FDA push­es back a re­view date for TG's 'U2' com­bo as the biotech steels it­self for up­com­ing ad­comm

The FDA has pushed back its re­view of TG Ther­a­peu­tics’ U2 com­bo (ubli­tux­imab plus Ukoniq) in pa­tients with chron­ic lym­pho­cyt­ic leukemia and small lym­pho­cyt­ic lym­phoma af­ter the drug­mak­er sub­mit­ted up­dat­ed sur­vival da­ta in Feb­ru­ary the agency deemed a ma­jor amend­ment to its ap­pli­ca­tion, ac­cord­ing to a re­lease.

The agency set a new re­view date of June 25, TG said.

The news wasn’t un­ex­pect­ed giv­en some of TG’s re­cent com­ments. In a state­ment, CEO Michael Weiss had this to say:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER